Endpoints
OS, PD‐L1
CPS, SECONDARY
The dual primary endpoints for nivolumab plus chemotherapy vs chemotherapy in the global population were OS and PFS per blinded independent central review (BICR) in patients with PD‐L1 CPS ≥5. Hierarchically tested secondary endpoints included OS in patients with PD‐L1 CPS ≥1 and in all randomized patients. Other secondary endpoints that were not formally tested included PFS and ORR per BICR at different PD‐L1 CPS cutoffs and in all randomized patients. Prespecified exploratory endpoints included DOR per BICR, landmark survival rates, biomarkers that were potentially associated with efficacy and safety and tolerability. The Chinese subgroup analysis includes data from the primary, secondary and key exploratory endpoints, but the endpoint analyses are descriptive.